For the Inventor, By the Inventor

Enter assignee name

Compugen Ltd. Corporation

USPTO Granted Patents = 62

% Expired Patents = 59.7

EPO Patents = 22

Trademarks = 6

Forward Citations = 777

Loading Chart...

Loading Chart...

143 inventors (with patents filed for the assignee):

Zurit Levine (31 out of 31 patents)

Amir Toporik (28 out of 28 patents)

Gad S Cojocaru (26 out of 26 patents)

4. Shirley Sameah-Greenwald (25 out of 25 patents)

5. Liat Dassa (20 out of 20 patents)

6. Zohar Tiran (19 out of 19 patents)

7. Dvir Dahary (18 out of 19 patents)

8. Amit Novik (18 out of 18 patents)

9. Ronen Shemesh (17 out of 17 patents)

10. Michal Ayalon-Soffer (17 out of 17 patents)

11. Spencer Liang (16 out of 19 patents)

12. Sarah Rachel Pollock (16 out of 19 patents)

13. Sandeep Kumar (15 out of 15 patents)

14. Christopher Chan (15 out of 17 patents)

15. Ilan Vaknin (15 out of 15 patents)

Core Competencies:

Anti-PVRIG Antibodies

Anti-TIGIT Antibodies

Polypeptides

Triple Combination Therapies

Cancer Treatment

Immune Disorders

Diagnostic Markers

Bioactive Peptides

G-Protein Coupled Receptors

Nucleotide Sequences

Splice Variants

Drug Targets

62 patents: Sort by Forward Citations

1. 12558421 - ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF (2026-02-24),

2. 12312404 - Anti-PVRIG antibodies and methods of use (2025-05-27),

3. 12152084 - Triple combination antibody therapies (2024-11-26),

4. 11795220 - Anti-PVRIG antibodies and methods of use (2023-10-24),

5. 11795209 - PVRIG polypeptides and methods of treatment (2023-10-24),

6. 11701424 - Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof (2023-07-18),

7. 11655297 - ILDR2 antagonists and combinations thereof (2023-05-23),

8. 11623955 - Anti-PVRIG antibodies and methods of use (2023-04-11),

9. 11225523 - Triple combination antibody therapies (2022-01-18),

10. 11220542 - Anti-PVRIG antibodies and methods of use (2022-01-11),

11. 10751415 - Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof (2020-08-25),

12. 10550173 - PVRIG polypeptides and methods of treatment (2020-02-04),

13. 10351625 - Anti-PVRIG antibodies and methods of use (2019-07-16),

14. 10227408 - Anti-PVRIG antibodies and methods of use (2019-03-12),

15. 10213505 - Anti-TIGIT anibodies, anti-PVRIG antibodies and combinations thereof (2019-02-26),

Company Overview

Compugen Ltd. Corporation, based in Holon, Israel, specializes in the development of innovative antibody therapies aimed at treating cancer and immune disorders. The company focuses on cutting-edge technologies, including anti-PVRIG and anti-TIGIT antibodies, as well as polypeptides and triple combination therapies. Compugen's research extends to identifying diagnostic markers and bioactive peptides, positioning it at the forefront of therapeutic advancements in oncology and immunology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

62 Patents

#1 in Holon

#92 in Israel

#11,768 in the World

Compugen Ltd. Corporation

Forward Citations = 777

143 inventors:

Zurit Levine (31 out of 31 patents)

Amir Toporik (28 out of 28 patents)

Gad S Cojocaru (26 out of 26 patents)

4. Shirley Sameah-Greenwald (25 out of 25 patents)

5. Liat Dassa (20 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Compugen Ltd. Corporation. Retrieved from https://idiyas.com/company/compugen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…